New findings explore the efficacy and safety of deucravacitinib in moderate-to-severe plaque psoriasis, including scalp outcomes and quality-of-life measures.
In this issue
Rate this content's potential impact on patient outcomes
Average rating / 5. Vote count:
No votes so far! Be the first to rate this content.
Latest articles
All articles


